Advertisement

Myleoma

#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma

May 20, 2022

...

Biochemical & Clinical Progression Outcomes in MM

May 17, 2022

Patients with clinically progressive MM have worse outcomes compared with biochemically progressive MM, but earlier therapy initiation can mean better outcomes.   “For patients with a...

Predicting Progression Risk in Asymptomatic Multiple Myeloma

Mar 22, 2022

Multiple myeloma (MM) is always preceded by a precursor condition called monoclonal gammopathy of undetermined significance and sometimes by an intermediate stage referred to as smoldering MM (SMM). T...

New Multiple Myeloma Staging System Provides Additional Data

Mar 11, 2022

Despite advances in multiple myeloma (MM) treatment, research suggests that survival outcomes can vary depending on factors that may be related to the tumor, the host, or both. “Different prognostic...

#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma

Feb 08, 2022

...

Improving Sentinel Node Positivity Risk Prediction in Patients With Melanoma

Dec 10, 2020

“Sentinel lymph node (SLN) biopsy provides valuable staging information—determining whether cutaneous melanoma has metastasized to regional lymph nodes—that can be used by clinicians to make inf...

Marital Status, Anatomic Location & Stage at Melanoma Diagnosis

Dec 08, 2020

“Stage is the most important prognostic factor in melanoma,” explains Saleh Rachidi, MD, PhD. “Melanoma in situ and early invasive melanoma can be treated with simple excision in the office, but...

Finding MDR With Liquid Biopsy for Multiple Myeloma

Aug 07, 2020

“A major obstacle to chemotherapeutic success in cancer treatment is the development of drug resistance, specifically multidrug resistance (MDR),” explains Mary Bebawy, PhD. “MDR is especially p...

ASCO: Gastric Cancer Patients Respond to Trastuzumab Deruxtecan

Jun 02, 2020

Overall survival also extended with conjugate treatment In a small, phase II trial, patients with advanced gastric cancer were far more likely to respond to conjugate therapy with trastuzumab deruxte...

ASCO: Oral GnRH Antagonist Superior to Leuprolide Injection in Prostate Cancer

Jun 02, 2020

HERO findings also confirm fewer cardiovascular events with relugolix More than 96% of men with advanced prostate cancer who were treated with relugolix, an oral, highly selective gonadatropin-releas...

ASCO: Virtual Meeting Kicks Off May 29

May 20, 2020

Three days packed with presentations The American Society of Clinical Oncology is the leading oncology research meeting worldwide, but just like other medical conferences, ASCO 2020 was forced to mak...

Article Addresses Management of Cancer Care During COVID-19

Mar 29, 2020

MONDAY, March 23, 2020 (HealthDay News) -- Management of cancer care during the coronavirus 2019 (COVID-19) pandemic is addressed in a special feature article published online March 20 in the Journal ...

Correlation between cytogenetic abnormalities and disease characteristics in multiple myeloma: monosomy of chromosome 13 and structural abnormalities of 11q are associated with a high percentage of S-phase plasma cells.

Jan 24, 2020

Cytogenetic studies in multiple myleoma (MM) are limited by the difficulties in obtaining metaphases that can be investigated and few studies have analyzed the relationship between cytogenetics and cl...

Randomized Phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma.

Jan 24, 2020

The potential synergistic anti-myeloma effect for thalidomide combining with interferon alpha was not yet clear clinically. From March 2001 to January 2004, a total of 28 heavily pretreated multiple m...

Bias analysis applied to Agricultural Health Study publications to estimate non-random sources of uncertainty.

Jan 24, 2020

The associations of pesticide exposure with disease outcomes are estimated without the benefit of a randomized design. For this reason and others, these studies are susceptible to systematic errors. I...

Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.

Jan 24, 2020

The cytokine-induced killer cells (CIK) have been reported to have potent cytotoxicity against a variety of tumor cells including multiple myleoma (MM) cells. The mechanisms that CIK cell recognizing ...

Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo.

Jan 24, 2020

Increased expression of the tetraspanin TSPAN7 has been observed in a number of cancers; however, it is unclear how TSPAN7 plays a role in cancer progression.We investigated the expression of TSPAN7 i...